Further exploration of GDF-15, uEGF, and other potential biomarkers of CKD progression in large multiethnic prospective pediatric cohorts including younger patients and children with earlier stages of CKD will be needed to corroborate and extend our findings with the aim of establishing reliable biomarker panels that will help personalize nephroprotective management for children with CKD, such as frequency of patient monitoring and timing of implementation of pharmacological therapies, according to individual risk. Here, GDF15 is linked to chronic kidney disease.